---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017561"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:47:18.297580+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Hookipa Q3 net loss $18.3M; cash $100.7M; secured Roche deal for KRAS-mutated cancers

## Summary
- Net loss $18.3M in Q3 2022 vs $20.0M in Q3 2021; revenue $2.2M (down from $3.9M).
- Cash $100.7M as of Sep 30, 2022 (up from $66.9M Dec 2021); excludes $25M Roche upfront and up to $30M Gilead stock purchase.
- Entered Roche collaboration for HB-700 (KRAS-mutated cancers) and second candidate; $25M upfront, potential $930M milestones plus royalties.
- FDA accepted IND for HB-300 (metastatic castration-resistant prostate cancer); Phase 1 start expected Q1 2023.
- Phase 2 HB-200 + pembrolizumab data expected H1 2023; >20 patients dosed, enrollment ongoing.

## SEC filing metadata
- accession: 0001558370-22-017561
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000155837022017561/0001558370-22-017561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000155837022017561/hook-20221114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017561
- JSON: https://secwatch.observer/filing/0001558370-22-017561.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017561.txt

## Key facts
- Earnings Releases
  HOOKIPA Pharma Inc. reported Third Quarter 2022 results: revenue $2.2 million, net income $18.3 million.
  - Period: Third Quarter 2022
  - Revenue: $2.2 million
  - Net income: $18.3 million
  - Result: reported results
  source text: stock that Gilead is required to purchase at the discretion of the Company pursuant to the terms of a stock purchase agreement signed in February 2022 ​ Revenue: Revenue was $2.2 million for the three months ended September 30, 2022, compared to $3.9 million for the three months ended September 30, 2021. The decrease was primarily due to lower cost reimbursements
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000155837022017561/0001558370-22-017561-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.